roche s elecsys anti sars cov 2 assay  (Roche)

Journal: The Journal of Prevention of Alzheimer's Disease

Article Title: Performance of a fully automated plasma tau phosphorylated at threonine 217 immunoassay to reflect amyloid-beta burden in an unselected cohort representative of clinical practice

doi: 10.1016/j.tjpad.2026.100534

Figure Lengend Snippet: Distribution of plasma pTau217 concentrations with respect to (A) clinical diagnosis and (B) centiloid values. (A) shows a boxplot, with the box itself representing the interquartile range. The median is represented by a solid horizontal line within the box. The whiskers extend from the box to the most extreme values, excluding outliers. (B) shows a scatterplot of centiloid values versus plasma pTau217 results (Pearson correlation coefficient, restricted to plasma pTau217 values within measuring range: 0.623).

Article Snippet: Moreover, high correlation has been demonstrated between the prototype Elecsys pTau217 plasma immunoassay and the Lumipulse G pTau217 plasma immunoassay from Fujirebio [ ]; in one of the reported head-to-head studies, the AUC for plasma pTau217 for detecting Aβ pathology was 0.907 (95 % CI: 0.858 to 0.957) with the prototype Elecsys pTau217 plasma immunoassay and 0.862 (95 % CI: 0.805 to 0.920) with the Lumipulse G pTau217 plasma immunoassay [ ].

Techniques: Clinical Proteomics, Biomarker Discovery

Journal: The Journal of Prevention of Alzheimer's Disease

Article Title: Performance of a fully automated plasma tau phosphorylated at threonine 217 immunoassay to reflect amyloid-beta burden in an unselected cohort representative of clinical practice

doi: 10.1016/j.tjpad.2026.100534

Figure Lengend Snippet: ROC analyses for plasma pTau217 by (A) centiloid-based classification at selected cutoffs and (B) clinical diagnosis at centiloid cutoff 30.

Article Snippet: Moreover, high correlation has been demonstrated between the prototype Elecsys pTau217 plasma immunoassay and the Lumipulse G pTau217 plasma immunoassay from Fujirebio [ ]; in one of the reported head-to-head studies, the AUC for plasma pTau217 for detecting Aβ pathology was 0.907 (95 % CI: 0.858 to 0.957) with the prototype Elecsys pTau217 plasma immunoassay and 0.862 (95 % CI: 0.805 to 0.920) with the Lumipulse G pTau217 plasma immunoassay [ ].

Techniques: Clinical Proteomics, Biomarker Discovery

Journal: The Journal of Prevention of Alzheimer's Disease

Article Title: Performance of a fully automated plasma tau phosphorylated at threonine 217 immunoassay to reflect amyloid-beta burden in an unselected cohort representative of clinical practice

doi: 10.1016/j.tjpad.2026.100534

Figure Lengend Snippet: Distribution of plasma pTau217 concentrations with respect to centiloid cutoff 30 (A) across all participants, (B) by clinical diagnosis, and (C) by eGFR status, using a double cutoff approach set at 90 % PPA and 90 % NPA. The box itself represents the interquartile range. The median is represented by a solid horizontal line within the box. The whiskers extend from the box to the most extreme values, excluding outliers. The double cutoffs are represented by grey lines. eGFR status was determined according to KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (all values in mL/min/1.73 m 2 ): ≥90, normal or high function (G1); 60 to 89, mildly decreased function (G2); 45 to 59, mildly to moderately decreased function (G3a); 30 to 44, moderately to severely decreased function (G3b); 15 to 29, severely decreased function (G4); and <15, kidney failure (G5). Thus, eGFR groupings for the purpose of analysis in this study were as follows (all values in mL/min/1.73 m 2 ): G1+G2 (≥60, mildly decreased to normal or high function), G3a (45 to 59, mildly to moderately decreased function), G3b (30 to 44, moderately to severely decreased function) and G4+G5 (≤29, severely decreased function to kidney failure) .

Article Snippet: Moreover, high correlation has been demonstrated between the prototype Elecsys pTau217 plasma immunoassay and the Lumipulse G pTau217 plasma immunoassay from Fujirebio [ ]; in one of the reported head-to-head studies, the AUC for plasma pTau217 for detecting Aβ pathology was 0.907 (95 % CI: 0.858 to 0.957) with the prototype Elecsys pTau217 plasma immunoassay and 0.862 (95 % CI: 0.805 to 0.920) with the Lumipulse G pTau217 plasma immunoassay [ ].

Techniques: Clinical Proteomics, Biomarker Discovery